Intercept Pharma withdraws liver disease drug from US market
US FDA says Intercept's drug can cause liver injury in patients without scarring
US FDA declines full approval for Intercept's liver disease drug
FDA advisers vote against confirmatory data for Intercept's liver disease drug
FDA staff raises efficacy concerns over Intercept's liver disease drug
Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium
Intercept to reduce work force by one third as it aims for profitability
US FDA declines to approve Intercept's fatty liver disease drug
Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)